Effect of phosphodiesterase inhibitors on human arteries in vitro

British Journal of Anaesthesia

Volumn 76, Issue 1, 1996, Pages 122-129

  Vroom, M B ^a   Pfaffendorf, M ^a   Van Wezel, H B ^a   Van Zwieten, P A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Arteries, relaxation; Pharmacology, glibenclamide; Pharmacology, nitric oxide; Pharmacology, phosphodiesterase inhibitors

Indexed keywords

DIPYRIDAMOLE; GLIBENCLAMIDE; MILRINONE; NITRIC OXIDE SYNTHASE INHIBITOR; PHENYLEPHRINE; PHOSPHODIESTERASE INHIBITOR; POTASSIUM CHANNEL; THROMBOXANE;

ARTERY; ARTERY DILATATION; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MYOGRAPHY; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE;

EID: 0030061647     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/76.1.122     Document Type: Article

References (38)

1. Butcher RW, Sutherland EW. Adenosine 3′,5′-phosphate in biological materials. Journal of Biological Chemistry 1962: 237; 1244-1250.
2. Beavo JA. Multiple isoenzymes of cyclic nucleotide phosphodiesterase. Advances in Second Messenger and Phosphoprotein Research 1988; 22: 1-37.
3. Weishaar RE, Burrows SD, Kobylarz DC, Quade MM, Evans DB. Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization and effects of various reference phosphodiesterase inhibitors and cardiotonic agents. Biochemical Pharmacology 1986; 5: 787-800.
4. Thompson WJ. Cyclic nucleotide phosphodiesterases: Pharmacology, biochemistry and function. Pharmacology and Therapeutics 1991; 51: 13-33.
5. Nicholson CD, Challis RAJ, Shahid M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends in Pharmacological Sciences 1991; 12: 19-27.
6. Packer M, Carver JR, Rodeheffer RJ, Ivanoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Malus GI, Sollano JA, Shannon J, Tandon PK, De Mets DL. Effect of oral milrinone on mortality in severe chronic heart failure: Promise study. New England Journal of Medicine 1991; 325: 1468-1475.
7. DiBianco R, Shabetia R, Kostuk W, Moran J, Schlant RC, Wright R. A comparison of oral milrinone, digoxin and their combination in the treatment of chronic heart failure. New England Journal of Medicine 1989; 320: 677-683.
8. Uretsky BF, Jessup M, Konstam MA, Dec W, Leier CV, Benotti J, Murali S, Herrmann HC, Sandberg JA. For the enoximone multicenter trial group. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Circulation 1990; 82: 774-780.
9. Dupuis JY, Bondy R, Cattran C, Nathan HJ, Wynands JE. Amrinone and dobutamine as primary treatment of low cardiac output syndrome following coronary artery surgery: A comparison of their effects on hemodynamics and outcome. Journal of Cardiothoracic and Vascular Anesthesia 1992; 6: 542-553.
10. Caldicott LD, Hawley K, Heppel R, Woodmansey PA, Channer KS. Intravenous enoximone or dobutamine for severe heart failure after acute myocardial infarction: a randomized double blind trial. European Heart Journal 1993; 14: 696-700.
11. Lindgren S, Andersson KE, Belfrage P, Degerman E, Manganiello VC. Relaxant effects of the selective phosphodiesterase inhibitors milrinone and OPC 3911 on isolated human mesenteric vessels. Pharmacology and Toxicology 1989; 64: 440-445.
12. m cyclic AMP system in vascular smooth muscle by milrinone. Journal of Pharmacology and Experimental Therapeutics 1988; 247: 34-42.
13. 2+ independent vasorelaxation induced by cardiotonic phosphodiesterase inhibitors. European Journal of Pharmacology 1993; 240: 57-66.
14. Kauffman RF, Schenck KW, Utterbach BG, Crowe G, Cohen ML. In vitro vascular relaxation by new inotropic agents: Relationship to phosphodiesterase inhibition and cardiac nucleotides. Journal of Pharmacology and Experimental Therapeutics 1987; 242: 864-872.
15. Weishaar RE, Burrows SD, Kobylarz DC, Quade MD, Evans DB. Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets: Isolation characterization and effects of various reference phosphodiesterase inhibitors and cardiotonic agents. Biochemical Pharmacology 1986; 35: 787-800.
16. Clarke WR, Soltow LOG. Amrinone causes vasodilation by both endothelium-independent and endothelium dependent mechanisms in small pulmonary arteries. American Review of Respiratory Diseases 1991; (Suppl A773).
17. Rosenblum WI, Shimizu T, Nelson GH. Interaction of endothelium with dilation produced by inhibitors of cyclic nuclide diesterases in mouse brain arterioles in vivo. Stroke 1993; 24: 266-270.
18. Martin W, Furchgott RF, Villani GM, Jothianandan D. Phosphodiesterase inhibitors induce eadothelium-dependent relaxation of rat and rabbit aorta by potentiating the effects of spontaneously released endothelium-derived relaxing factor. Journal of Pharmacology and Experimental Therapeutics 1986; 237: 539-547.
19. Grover GJ, Sleph PG, Dzwonczyk S. Role of myocardial ATP-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interaction with adenosine A, receptors. Circulation 1992; 86: 1310-1316.
20. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circulation Research 1992; 70: 223-233.
21. Southard JH, Van Gulik TM, Ametani MS, Vreugdenhil PK, Lindell SL, Pinaar BL, Belzer FO. Important components of the LTW solution. Transplantation 1990; 49, 251-257.
22. Mulvany MJ, Halpern W. Mechanical properties of vascular smooth muscle cells in situ. Nature (London) 1976; 260: 617-618.
23. Mulvany MJ, Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circulation Research 1977; 41: 10-26.
24. Fredholm BB, Persson CGA. Xanthine derivatives as adenosine receptor antagonists. European Journal of Pharmacology 1982; 81: 673-676.
25. Persson CGA, Andersson KE, Kjellin G. Effects of enprofylline and theophylline may show the role of adenosine. Life Sciences 1986, 38: 1057-1072.
26. Kubler W, Spieckermann PA, Bretschneider HJ. Influence of dipyridamole (Persantin) on myocardial adenosine metabolism. Journal of Molecular and Cellular Cardiology 1970; 1: 23-27.
27. Klabunde RE. Effects of dipyridamol on postischemic vasodilation and estracellular adenosine. American Journal of Physiology 1983; 244: H273-H280.
28. Weishaar RE, Kobylarz-Singer DC, Steffen RP, Kaplan HR. Subclasses of cyclic AMP, specific phosphodiesterase in left ventricular muscle and their involvement in myocardial contractility. Circulation Research 1987; 61: 539-547.
29. Lindgren S, Andersson KE. Effects of selective phosphodiesterase inhibitors on isolated coronary, lung and renal arteries from man and rat. Acta Physiologica Scandinavica 1991; 142: 77-82.
30. Harris AL, Grant AM, Silver PJ, Evans DB, Alousi AA. Differential vasorelaxant effects of milrinone and amrinone on contractile responses of canine coronary, cerebral, and renal arteries. Journal of Cardiovascular Pharmacology 1989; 13: 238-244.
31. Ploeg RJ, Goossens D, McAnulty JF, Stouthard JH, Belzer FO. Successful 72 hour cold storage of dog kidneys with UW solution. Transplantation 1988; 46: 191-196.
32. Wahlberg JA, Love R, Landegaard L, Stouthard JH, Belzer FO. 72 hours preservation of the canine pancreas. Transplantation 1987; 43: 5-8.
33. Butt AY, Dinh-Xuan AT, Pepke-Zaba J, Cremona G, Clelland CA, Higenbottam TW. In vitro pulmonary vasorelaxant effect of the phosphodiesterase inhibitor enoximone. Angiology 1993; 12: 289-294.
34. Mayer B, Brunner F, Schmidt K. Novel actions of methylene blue. European Heart Journal 1993; 14: (Suppl. I) 22-26.
35. Jiang J, Colbran JL, Francis SH, Corbin JD. Direct evidence for cross-activation of cGMP-dependent protein kinase by cAMP in pig coronary arteries. Journal of Biochemical Chemistry 1992; 267: 1015-1019.
36. Lugnier C, Komas N. Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP:role in vasodilatation. European Heart Journal 1993; 14 (Suppl. I): 141-148.
37. Fujimoto S. Effects of pimobendan, its active metabolite UD-CG 212 and milrinone on isolated blood vessels. European Journal of Pharmacology 1994; 265: 159-166.
38. Ashcroft FM. Adenosine 5′-triphosphate-sensitive potassium channels. Annual Review of Neuroscience 1988; 11: 97.